Zidovudine (Zidine) is commonly used for managing Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. The therapeutic domains center on chronic disease control and support the immune system. The primary indications are for asymptomatic infection, Acquired Immunodeficiency Syndrome (AIDS), and AIDS-Related Complex (ARC).

Its use contributes to supporting CD4 cell counts, which may assist in reducing the likelihood of severe complications and opportunistic infections. This is done primarily by addressing the systemic viral load and helping to manage disease progression. The medication is also relevant in preventive clinical scenarios, particularly when it is applied in addressing the risk of mother-to-child HIV transmission during pregnancy and labor, and in specific contexts such as Post-Exposure Prophylaxis (PEP). In these situations, it assists with maintaining functional stability.

“The use of this medication helps patients cope more steadily with the symptom fluctuations inherent in the condition, providing supportive relief that maintains a sense of stability.”

---

Quick Fact: Relief for Systemic Imbalance

Zidovudine is used for managing conditions marked by a high systemic viral burden, helping to manage symptoms related to systemic imbalance and contributing to improved day-to-day comfort.

Regulatory References

1. NIH DailyMed official label

Who can and cannot use Zidine?

The official eligibility profile for Zidine (Zidovudine) is determined by regulatory agencies based on age, physiological status, and underlying conditions.

Contraindicated and Restricted Populations

Zidine is contraindicated and must not be used by patients with a known hypersensitivity reaction to Zidovudine or any components of the drug. Use is also contraindicated in newborn infants with severe hyperbilirubinaemia or highly elevated liver transaminase levels.

Population Group	Eligibility Status (Official Labeling)
Adults and Children	Approved for treatment from 4 weeks of age onwards.
Older Adults	Special care is advised due to potential age-related changes in organ function.
Pregnant Women	Use is recommended for the specific purpose of preventing mother-to-child HIV transmission.
Lactating Women	Not recommended due to the risk of HIV transmission to the infant.

Eligibility is conditional for patients with impaired organ function. Individuals with severe renal failure (creatinine clearance below 10 mL/minute) or severe hepatic impairment require mandatory dose adjustment. Furthermore, patients with bone marrow compromise (low hemoglobin or granulocyte count) require close monitoring and may need temporary treatment interruption.

The official regulatory documents define the interaction profile of Zidovudine (Zidine) through specific pharmacokinetic, pharmacodynamic, and administrative constraints.

Contraindicated Combinations and Toxicological Reinforcement

Co-administration with other Zidovudine-containing products is strictly prohibited. Combinations with certain other antiretroviral agents, specifically Stavudine and Doxorubicin, should be avoided due to documented in vitro antagonistic antiviral activity. Furthermore, co-administration with bone marrow suppressive or cytotoxic agents increases the officially stated risk of hematologic toxicity, including severe neutropenia and anemia. Co-use with Ribavirin is also advised against due to the risk of exacerbating anemia.

Exposure-Altering Interactions and Metabolic Pathway

Several medicines are documented to increase Zidovudine's systemic exposure by interfering with its clearance. Probenecid, Valproic acid, and Acetaminophen all interfere with Zidovudine's metabolism via the glucuronidation pathway, leading to increased plasma concentrations. Similarly, Trimethoprim is officially stated to inhibit Zidovudine's renal elimination. Substances like Methadone, Nelfinavir, and Tipranavir also have documented interactions resulting in increased Zidovudine exposure.

Administration Constraints and Population Notes

A mandatory time separation rule exists for Activated charcoal, which must be administered at least 4 hours apart from Zidovudine to prevent reduced absorption. The administration of Zidovudine with food slows the rate of absorption but does not significantly alter the total amount absorbed. Caution is advised regarding alcohol use due to its potential contribution as a risk factor for hepatic steatosis, a condition associated with Zidovudine. Interaction constraints extend to specific patient groups, as patients with severe renal impairment have documented increased Zidovudine concentrations due to decreased clearance.

Zidine's mechanism of action begins with the drug's active form, Zidovudine Triphosphate (ZDV-TP), which acts as a competitive inhibitor of the viral enzyme, Reverse Transcriptase. This molecular targeting interferes with the enzyme's ability to utilize the natural building blocks of DNA, thereby commencing a cascade that restricts the proliferation of retroviral genetic material.

The key mechanistic domain is the physical stoppage of the viral genetic process: ZDV-TP is incorporated into the nascent proviral DNA chain due to its close resemblance to a natural nucleoside. However, lacking a critical 3'- OH group, the drug acts as a DNA chain terminator, preventing the attachment of subsequent nucleotides. This blockade of proviral DNA synthesis disrupts the process of creating the genetic template required for new viral particle production.

While primarily targeting the viral enzyme, the drug's action is constrained by two major mechanistic factors: the dependency on host Intracellular Kinases for activation, which dictates onset, and a potential lack of absolute selectivity. At higher concentrations, ZDV-TP can also inhibit the host's Mitochondrial DNA Polymerase gamma, which places a functional constraint on the mechanism despite its action against the primary viral target.

Zidine (Zidovudine) is administered via oral intake (as tablets, capsules, or solution) for chronic maintenance, and intravenous (IV) infusion for specific contexts, such as the intrapartum period or when oral administration is not feasible. The IV form is used only until the patient can transition back to oral dosing.

The standard oral regimen for adults in combination therapy is typically 600 mg per day, most often divided and taken as 300 mg twice daily. The tablets may be administered with or without food, providing flexibility for the dosing schedule. When children cannot swallow solid forms, specialized scored tablets can be crushed and mixed with water only for immediate intake.

Official Usage Patterns

Clinical Context	Administration Route & Frequency
Chronic HIV Treatment (Adult)	Oral, typically twice or three times daily
PMTCT (Intrapartum)	IV infusion, involving a loading dose followed by continuous infusion
Neonatal PMTCT Course	Oral solution/syrup, typically 2 mg/kg every 6 hours for 6 weeks

Specific usage constraints require the dosage to be adjusted for individuals with severe renal impairment, necessitating a reduced dose, such as 100 mg every 6 to 8 hours. In cases requiring such adjustments, single-entity Zidovudine formulations must be used, as fixed-dose combination products do not permit individual dose modification. If a scheduled dose is missed, patients should take the next dose at the regularly scheduled time and should not double the dose.

Research Evidence / Overview of Studies for Zidine

This section summarizes the types of official research that has been reported for Zidovudine (Zidine) and describes the findings that have been reported by regulatory and peer-reviewed sources. The summary focuses on the clinical evaluation of Zidovudine (Zidine) and its research patterns, using strictly neutral and patient-friendly language.

---

Evidence for use in Managing Established HIV-1 Infection

Early research on Zidovudine was conducted through controlled trials, including Randomized Controlled Trials (RCTs), as well as longer-running observational studies. These studies examined Zidovudine's role as a component within combination therapy.

The research primarily monitored outcomes reflecting systemic functioning, such as measuring changes in the amount of virus in the blood (HIV viral load) and tracking the levels of immune system cells, specifically the CD4 cell counts. Research reported patterns related to changes in these key markers when Zidovudine was used as part of a combination regimen. These findings describe patterns observed in the studies related to the time elapsed before patients experienced further signs of disease progression.

Key Limitations and Research Scope: Initial pivotal trials relied on Zidovudine as the only treatment (monotherapy). Data show patterns related to certain dose-limiting effects that were associated with those monotherapy regimens. Because current treatment standards rely on multi-drug regimens, Zidovudine is now evaluated and used exclusively in combination regimens.

---

Evidence for use in Preventing Mother-to-Child Transmission

The principal evidence for using Zidovudine to address the risk of mother-to-child transmission is derived from a landmark randomized, double-blind, placebo-controlled trial. This research was applied in studies focusing on episodes where symptoms become more noticeable, such as during pregnancy and delivery, primarily measuring the rate of HIV-1 infection in the infant at specific follow-up points.

The seminal study reported observations where the rate of transmission of the virus from mother to infant appeared reduced in the group that received Zidovudine compared to the placebo group. Follow-up research helped contextualize how patients reported their experience when Zidovudine was administered to the mother during pregnancy and labor, followed by the infant shortly after birth.

---

Research Context for Post-Exposure Prophylaxis (PEP)

For use as Post-Exposure Prophylaxis (PEP) following a potential exposure to the virus, the evidence base relies primarily on observational studies and data extrapolated from treatment trials, that regulators rely on to support Zidovudine's approved indication in combination regimens. Dedicated, large-scale, placebo-controlled RCTs are lacking due to ethical constraints.

Research has described patterns reported in studies that tracked the incidence of new infection following prompt initiation of a Zidovudine-containing PEP regimen compared to control groups or historical rates. Findings indicate that adherence to the full 28-day course of therapy was a critical factor monitored in these cohorts.

Key Studies & References

1. Zidovudine for the Prevention of HIV Transmission from Mother to Infant (ACTG 076 Trial Summary)
2. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIVS
3. Post-Exposure Prophylaxis (PEP) - HIV Prevention (Guidance on Observational Data and Use)

Common questions about Zidine (FAQ)

Q: Who is generally advised not to use Zidine?

Zidovudine is contraindicated (is not recommended for use) if a patient has a known hypersensitivity reaction to any component of the medicine. Official labeling also suggests caution for patients with existing severe blood disorders, such as severe anemia or severe neutropenia, which may necessitate temporary interruption of the medicine.

Q: Is Zidine classified as a controlled substance?

Zidovudine is not classified as a controlled substance by US or international regulatory authorities.

Q: Is there any research looking at Zidine and long-term use?

Yes, research and official product labeling document risks associated with the prolonged use of Zidovudine. For instance, symptomatic myopathy (a type of muscle disease) is a documented risk linked to long-term use. Therefore, close observation for these symptoms may be part of the recommended care plan.

Q: Do you need a prescription from a doctor to get Zidine?

Yes, Zidovudine is classified as a prescription-only medication by regulatory bodies. Access to the drug requires a prescription from a licensed healthcare professional.

Q: Is Zidine considered a high-alert medication?

Due to the Boxed Warning highlighting the risks of life-threatening toxicities, Zidovudine is a medication that requires careful and consistent monitoring during its use. This caution is specified in regulatory documents.

Q: Why do doctors prescribe Zidine for multiple conditions?

Zidovudine has been prescribed for multiple, specific conditions because it holds regulatory approval for more than one indication. These include the long-term treatment of HIV-1 infection and, separately, the prevention of HIV-1 transmission from mother to child during pregnancy and delivery (PMTCT).

Q: What are the serious side effects that have been officially reported for Zidine?

Official documents report several serious risks, including severe hematologic toxicity, which involves severe anemia (low red blood cell count) and neutropenia (low white blood cell count). Other serious risks include myopathy (muscle disease) and lactic acidosis (a buildup of lactic acid in the blood) combined with severe hepatomegaly, which is an enlarged liver with fat accumulation.

Q: Can Zidine affect sleep patterns?

Yes, insomnia (which means difficulty falling or staying asleep) is listed in the official safety information as a commonly reported adverse reaction to the medicine.

Q: Are there different brand names for the medicine Zidine?

Yes, the active ingredient Zidovudine has been marketed under various names. The original brand name that received regulatory approval is Retrovir.

Q: How long does Zidine stay in the body?

Regulatory pharmacokinetic data indicates that the terminal elimination half-life of Zidovudine in adults is short, generally ranging from 0.8 to 1.1 hours. The half-life is the time it takes for half of the drug to be cleared from the bloodstream.

Q: Is there a generic version of Zidine available?

Yes, according to official drug listings and health authorities, generic formulations of Zidovudine are available on the market.

Q: What is the purpose of Zidine's black box warning, if it has one?

The Boxed Warning is a required regulatory tool used to highlight serious and potentially life-threatening risks associated with the medicine. For Zidovudine, this warning alerts prescribers and patients to the risks of severe blood disorders (hematologic toxicity), muscle disease (myopathy), and lactic acidosis combined with severe liver enlargement.

Q: Can Zidine interact with common over-the-counter pain relievers?

Yes, official product documents note that Zidovudine can interact with certain common over-the-counter pain relievers, such as acetaminophen. This interaction can slow the rate at which the body clears Zidovudine, leading to higher concentrations in the bloodstream.

Q: What is the expected duration of treatment with Zidine?

The expected duration of use is determined by the condition being addressed, as it varies significantly by indication. The medicine is approved for chronic, long-term use as part of HIV combination therapy, but it is also used temporarily for specific courses, such as the 6-week regimen for newborns.

Q: Does Zidine cause weight change?

Official safety information includes reports of weight loss/anorexia (loss of appetite) as an adverse reaction. Additionally, long-term use has been associated with lipodystrophy, which is a change in the way the body stores and distributes fat.

Q: Is Zidine safe to use for older adults?

Regulatory information advises that special care be taken when Zidovudine is prescribed to older adults. This caution is due to potential age-related changes in organ function, such as kidney or liver function, which might necessitate a dose adjustment.

Q: What should I do if I think I am having a rare or serious reaction to Zidine?

The official label provides strong direction that a healthcare provider should be contacted immediately if a patient experiences signs or symptoms of a serious adverse reaction. This caution applies to symptoms related to severe blood disorders or conditions like lactic acidosis.

Q: What kind of monitoring might a doctor recommend while taking Zidine?

Official regulatory documents require close monitoring for patients using the medicine. This typically involves blood tests, such as regular measurement of blood cell counts (like hemoglobin and neutrophil counts), to check for signs of hematologic toxicity.

Q: Is Zidine known to cause problems with the liver?

Yes, the official Boxed Warning highlights the risk of severe hepatomegaly, which is an enlarged liver, often accompanied by steatosis (fatty liver). Because of this risk, regulatory documents specify that liver function tests may be monitored throughout the course of treatment.

Q: Why does Zidine have restrictions on use with certain foods or beverages?

The caution regarding food is informational, as it is known to slow the rate at which the medicine is absorbed, though it may be taken with or without food. The caution regarding alcohol is due to its potential to increase the risk of hepatic steatosis (fatty liver), which is a serious adverse effect associated with Zidovudine.

Q: What are the signs that Zidine is working for the condition it treats?

The effectiveness of the drug is assessed in clinical settings by laboratory measures, primarily tracking changes in the viral load (the amount of virus in the blood) and increases in specific immune cells, known as CD4 cell counts.

Q: Is Zidine part of a drug class commonly used for [broad therapeutic area]?

Yes, the medicine belongs to a class known as Nucleoside Reverse Transcriptase Inhibitors (NRTIs). This class of drugs is a foundational component of combination regimens used to treat retroviral infections.

Q: Does taking Zidine require special tests beforehand?

Regulatory information indicates that patients may be assessed for underlying conditions, particularly if there is a history of bone marrow compromise or low blood cell counts. Specific blood tests, such as hemoglobin or neutrophil counts, may be conducted before starting the medicine to guide therapy.

Q: Are there specific patient populations that respond differently to Zidine?

Official documents specify that patient populations with severe renal (kidney) or hepatic (liver) impairment may require dosage adjustment. This is typically due to the way these conditions may change how the body processes and eliminates the drug.

Q: Does Zidine interact with birth control pills?

According to official clinical guidelines, Zidovudine is generally considered to have no significant pharmacokinetic interaction with hormonal contraceptives. Unlike some other medications, it does not typically affect the liver enzymes that process birth control pills.

Q: Is Zidine intended to be used temporarily or long-term?

Zidovudine is used for both temporary and long-term treatment based on the regulatory indication. It is utilized as a component of chronic, long-term combination therapy for HIV-1 infection, but also in specific temporary regimens, such as the 6-week course for newborns.

Q: What are the most common side effects reported for Zidine?

Official product information states that the most commonly reported side effects in adult clinical trials include headache, nausea, vomiting, and a general feeling of discomfort (malaise). Loss of appetite (anorexia) is also frequently reported.

Q: Are there any widely known products or supplements that interact with Zidine?

The regulatory documents primarily focus on known interactions with other prescription medications. Since official sources do not typically provide a complete review of all dietary supplements, the official recommendation is that the patient's healthcare provider should be informed of all supplements being taken.

Q: Is Zidine approved for use in children?

Yes, Zidovudine is approved by regulatory bodies for use in pediatric patients for the treatment of HIV-1 infection. The official label indicates approval for use starting at 4 weeks of age and older.

Q: Does Zidine have a warning about driving or operating machinery?

The official label notes that common side effects such as fatigue, headache, and a general feeling of discomfort may affect your ability to drive or operate machinery. Regulatory information advises caution if you plan to engage in these activities while using the medicine.

Q: What are the official cautions for stopping Zidine use?

Official regulatory cautions indicate that interruption of the medicine should not occur without consulting a healthcare provider first. This consultation is particularly important when discontinuation is being considered due to laboratory findings suggestive of severe issues like lactic acidosis or severe blood disorders (hematologic toxicity).

How to Store and Dispose of Zidovudine

Official regulatory guidelines mandate specific storage conditions to preserve product quality and safety.

---

Required Storage and Protection

Dosage Form	Required Temperature	Environmental Rules
Tablets	Controlled Room Temperature (20 C to 25 C)	Protect from excess heat and moisture
Capsules/Oral Solution	15 C to 25 C	Protect from light and do not freeze

Zidovudine must be kept in its tightly closed, original container and stored out of the reach of children. The medicine should not be used if the container's original seal is broken. The diluted intravenous solution has a limited shelf-life and must be used within 8 to 24 hours, depending on the storage temperature.

---

Disposal Instructions

Unused or expired Zidovudine must be thrown away according to established guidelines for safe drug disposal. Patients must follow the official instructions provided by their national health authority for discarding unused medicine.